Drug Discovery@nature.com 24 August 2012

TABLE OF CONTENTS 24 August 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Now accepting submissions Open Access - Peer Review - Renowned International Editorial Board A new online open access journal in the pharmacometrics and systems pharmacology space.   News Top How the brain cleans itself doi:10.1038/nature.2012.11216 Fluids coursing through the nervous system could help clear the brain of toxic detritus that leads to Alzheimer's and Huntington's disorders. Full Text Road to unitary European patent hits a bump doi:10.1038/nrd3820 Progress towards the establishment of a single European patent system recently encountered a setback because of last-minute proposed changes to the draft legislation. Full Text Investors boost Canadian startups but public sector underperforms doi:10.1038/nbt0812-737 Recent deals suggest that, despite plummeting revenues and R&D expenditures, big pharma sees untapped potential in the translational science coming out of Canada. Full Text Cautious optimism surrounds early clinical data for PD-1 blocker doi:10.1038/nbt0812-729 Early-stage trial results have heightened expectations surrounding a new class of anticancer immunotherapies that block the programmed cell death 1 (PD-1) receptor. Full Text Analysis Top Tracing cancer stem cells doi:10.1038/scibx.2012.830 Three teams have independently developed techniques for in vivo detection of cancer stem cells in mice. The methods could be useful as next-generation target discovery platforms and screens for compounds targeting cancer stem cells. Full Text Fresh from the pipeline: Pasireotide doi:10.1038/nrd3788 In April 2012, pasireotide was granted European marketing authorization for the treatment of Cushing's disease, providing a new option for patients for whom surgery has failed. Full Text From the analyst's couch: A new dawn in the sleep disorders pipeline? doi:10.1038/nrd3789 This analysis article looks at the growing interest in novel molecular targets for sleep disorders, and the market opportunities in this area of significant unmet need. Full Text Research Highlights Top Cancer: PD1 makes waves in anticancer immunotherapy doi:10.1038/nrd3806 Two papers describe early-stage clinical trials of two monoclonal antibodies that target signalling through the T cell co-inhibitory receptor programmed cell death protein 1, suggesting that such antibodies might provide a new benchmark for anticancer immunotherapy. Full Text Metabolic disorders: New target for appetite control doi:10.1038/nrd3803 The G protein-coupled receptor GPR17 has been identified as a direct target of the forkhead box protein O1 transcription factor, which activates AGRP-expressing neurons to regulate food intake in mice. Full Text Neurodegenerative disorders: Reversing Huntington's disease doi:10.1038/nrd3804 New research shows that transient infusion of single-stranded antisense oligonucleotides in a mouse model results in sustained improvements in motor function and behaviour. Full Text Research & Reviews Top Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases doi:10.1038/nrd3800 This review looks at current and future drugs that may be available to treat a broad range of inflammation-related conditions by blocking interleukin-1. Full Text G protein-coupled receptors for energy metabolites as new therapeutic targets doi:10.1038/nrd3777 This review summarizes the functions of several recently discovered metabolite-sensing GPCRs and discusses the emerging pharmacological agents being developed to target these for metabolic disorders. Full Text A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response doi:10.1038/nature11262 A paper in Nature provides encouragement for designing small-molecule inhibitors to allow selective pharmacological intervention across the JMJ family. Full Text MDM4 is a key therapeutic target in cutaneous melanoma doi:10.1038/nm.2863 A paper in Nature Medicine identifies MDM4 as a key determinant of impaired p53 function in human melanoma and designates MDM4 as a promising target for antimelanoma combination therapy. Full Text Drug Discovery JOBS of the week Drug Discovery Researcher Monash University 4 Tenure Track Positions-Diagnostics, Targeted Therapy, Imaging Guided Therapy, Drug Delivery Georgia State University Postdoctoral Research Associate - Drug Metabolism and Pharmacokinetics Scripps Fl Principal Investigator positions in Biological Chemistry & Drug Discovery University of Dundee, College of Life Sciences More Science jobs from Drug Discovery EVENT Combination Products Workshop � Regulatory Overview for Drug/Device Combinations and Drug/Companion Diagnostics 18.09.12 Basel, Switzerland More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.